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ABSTRACT 
Gastroesophageal reflux disease (GERD), or acid reflux, affects 6-9 million people in the United 
States. It is characterized by a reflux of gastric acid and bile salts from the stomach into the 
esophagus, causing injuries to the esophagus known as Barrett’s esophagus (BE). BE is the main 
risk factor for the development of esophageal adenocarcinoma (EAC), a devastating cancer in the 
esophagus whose molecular roots remain poorly understood. In recent years, evidence points to 
the esophageal epithelium itself as responsible for causing and promoting inflammation upon 
injury by gastric reflux, namely via an increase in inflammatory cytokine secretion.  This project 
was focused on a cytokine of interest, Activin A, which is known for its importance during 
embryogenesis and stem cell differentiation. It has recently been studied for its role in 
inflammation and tumor formation, but not in the case of esophageal diseases. Here, we 
demonstrate that Activin A signaling in esophageal epithelial cells is heavily upregulated shortly 
after exposure to bile salts and acid. We show evidence that this upregulation causes an increase 
in cell migration upon a reconstituted extracellular matrix. We also provide further evidence that 
bile and acid injury causes epithelial cells to secrete cytokines, which drive inflammation. We 
show that the upregulated Activin A secretion and signaling plays an important role in promoting 
this inflammatory state. Finally, we provide evidence that bile salts and acid exposure, as well as 
increased Activin A signaling, causes esophageal epithelial cells to upregulate stem cell and 
transdifferentiation markers, supporting the latest theories on the origin of Barrett’ esophagus 
stem cells as well as paligenosis.   
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INTRODUCTION 
Esophageal adenocarcinoma (EAC) is a serious cancer of the distal esophagus. Its incidence has 
dramatically increased in developed nations over the past 40 years, and it is now the sixth most 
common cause of cancer-related deaths worldwide and eleventh in the United States1, 2. EAC is a 
difficult cancer to manage and its 5-year survival rate is below 20%2.  
One of the most well-known risk factors for EAC is gastroesophageal reflux disease (GERD), 
also known as gastric reflux or acid reflux. GERD affects approximately 6-9 million people in 
the United States3, and when acute is commonly referred to as heart burn. GERD is caused by 
the chronic reflux of gastric contents including acids and bile salts from the stomach into the 
esophagus. The prolonged exposure of normal esophageal epithelium to these harsh gastric 
chemicals causes a metaplastic change from a stratified squamous epithelium to an intestinal 
columnar epithelium called Barrett’s esophagus (BE). Multiple studies have shown that BE is 
one of the main factors for the development of EAC4.   
Much remains to be learned about the development and progression from GERD to EAC. 
Particularly, the biochemical and molecular roots of this progression remain largely unknown. 
The main goal of this research project was to evaluate one particular cell signaling pathway, 
namely Activin A signaling, at the onset of GERD. Dysregulation of Activin A signaling has 
been shown to promote lung cancer and colorectal cancer, but its role is poorly defined for EAC. 
Particularly, Activin A signaling has never been studied in the context of GERD-related diseases, 
and its role in the progression from normal esophageal epithelium to Barrett’s esophagus is 
unknown.  
2 
 
The work presented here has shed light on the topic of Activin A signaling in GERD-related 
diseases. Our findings have elucidated the effects of GERD-like injuries on Activin A signaling. 
We have described the role of Activin A signaling in the inflammatory signaling response caused 
by bile salts and acid in esophageal epithelial cells. Finally, we contributed to the latest work 
done in the field of gastroesophageal diseases, particularly on the theories of precursor cells for 
Barrett’s esophagus.  
The data presented in this project will be able to directly impact the latest areas of 
gastroesophageal research including the signaling pathways involved in the GERD to EAC 
progression, the theories on the origin of BE stem cells, as well as the theories on cellular 
reprogramming and paligenosis5. Together, we hope that this new information will lead to a 
better understanding of the onset of gastroesophageal diseases and potentially new therapeutic 
strategies. 
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BACKGROUND AND SIGNIFICANCE 
Since 1975, the incidence of esophageal adenocarcinoma (EAC) has increased as much as 460% 
throughout Europe and North America1. It presents many challenges, including poor survival 
rates due to late diagnosis and lack of effective screening methods4, 6. The risk factors for EAC 
include tobacco smoking, obesity, advanced age, and most importantly gastroesophageal reflux 
disease (GERD). In GERD, acidic contents from the stomach spill into the esophagus, thereby 
injuring the epithelial lining and causing heartburn to the patient. Over time, exposure to the 
acidity and other secretions such as bile salts results in injuries to the esophageal epithelium. 
Consequently, the squamous epithelium experiences a histological transition to an intestinal 
columnar epithelium, otherwise known as Barrett’s esophagus (BE). Barrett’s and GERD are 
major risk factors for EAC. Studies have shown that patients with chronic GERD have between a 
5-fold to 8-fold increased risk of developing EAC7, 8, 9. In summary, the development of EAC 
from normal esophageal epithelium follows an overall pattern:  
The earliest theories about this progression hypothesized that the state of inflammation found in 
GERD and BE could be explained solely by the physical injuries caused by the acid exposure in 
the esophagus. It was thought that the refluxing stomach acid caused a physical degradation of 
the tissue and an open wound in the esophageal epithelium. It was thought that the cells that 
came in and replaced the damaged tissue were metaplastic, intestinal-like cells characteristic of 
Figure 1: GERD to EAC progression. 
4 
 
BE. The wound healing process was also responsible for recruiting more immune cells and 
promoting the state of inflammation see in BE10.  
In recent years, this theory has been largely replaced and as more evidence points to the 
importance of the injured epithelium as the key factor for inducing the inflammatory response. 
Following reflux from stomach contents on the esophageal epithelium, epithelial cells actually 
do not undergo early apoptosis and get replaced. Instead, there is an abundance of evidence that 
injured cell are triggered to produce inflammatory cytokines, which then attract the immune cells 
and cause the observed inflammatory response10-13. 
We now know that inflammatory cytokines produced by acid and bile-injured epithelial cells 
play an important role in promoting inflammation and disease progression shown in figure 1. In 
addition, molecular mechanisms that drive the progression have been reported, and the impact of 
acid and bile salts at various parts of this progression have been studied in the past as well.  
For example, acid exposure has been shown to significantly reduce apoptosis and increase the 
proliferation of esophageal adenocarcinoma cells via disruption of p53-dependent mechanisms, 
as well as disruption of the mitogen-activated protein kinase (MAPK) pathways, which are 
involved in cell growth regulation14, 15. In such way, bile salts may have an important role in the 
uncontrolled proliferation of esophageal adenocarcinoma cells. Bile salts have also been shown 
to increase the proliferation of Barrett’s cells through the same MAPK pathways, indicating that 
dysregulation of these pathways could play an important role in the progression of the cancer16. 
In addition, the homeobox protein CDX-2, which is expressed as a result of the GERD and 
tightly associated with the emergence of Barrett’s metaplasia, has been shown to play a pivotal 
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role in the intestinal differentiation of esophageal epithelial cells to columnar Barrett’s cells upon 
exposure to various bile acids17. NFκB transcription factors are important mediators of 
inflammation. Two NFκB transcription factor binding sites in the CDX2 promotor were also 
shown to regulate the differentiation effect of CDX-2 itself17, therefore contributing to the 
progression of the cancer. 
Finally, DNA damage caused by the components of the gastric refluxate has been shown to 
contribute to the progression of esophageal adenocarcinoma. Indeed, normal esophageal cells 
exposed to bile salts such as sodium glycocholate, glycocholic acid, sodium taurocholate, and 
taurochenodeoxycholate show a significant increase in DNA damage that contribute to the 
overall the progression of the cancer18. 
The studies mentioned above are important findings that give us valuable insight into the 
progression from GERD to EAC. However, these studies, as well as most research in the field of 
gastroesophageal diseases to date, have focused on the latter part of the progression, namely BE 
to EAC. Indeed, the majority of research about this topic involves studies on metaplastic 
Barrett’s esophagus cell lines or directly esophageal adenocarcinoma cells themselves. The 
clinical studies also mostly involve patients with esophagitis or already diagnosed with BE or 
EAC. Only a small amount of research has been dedicated to the onset of the disease, when 
esophageal epithelial cells are still normal and the chronic acid reflux is beginning to take place. 
This is the area that this research project addressed.   
In recent years, Activin A, a regulatory cytokine that is part of the transforming growth factor β 
(TGFβ) superfamily, has been increasingly studied for its role in carcinogenesis. Activin A is a 
6 
 
protein composed of two Activin βA subunits that join to form a dimer (βAβA). Two membrane-
bound, Activin A-specific receptors (Activin Receptors IB and IIB – ACRIB and ACRIIB) 
regulate its cellular signaling via different pathways.  
Activin A signaling is known to proceed through a canonical and non-canonical pathway19 
(figure 2 – A-B). The canonical pathway involves the Smad proteins as direct targets. Upon 
Activin A binding to the receptor, Smad2/3 gets phosphorylated and a complex with Smad4 is 
formed. This complex is translocated to the nucleus, where it will bind DNA and affect gene 
Figure 2: Canonical and non-canonical pathways of Activin A signaling. 
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transcription. The non-canonical pathway mediates the signal through a different set of 
intermediates, namely the mitogen-activated protein kinase (MAPK) pathways, p21 or β-
Catenin. 
Activin A signaling is best known for playing a crucial role during embryogenesis and human 
development. It also participates in stem cell differentiation and Epithelial-Mesenchymal 
Transition (EMT). In the skin, Activin A has been shown to play an important role in promoting 
wound healing and mediates inflammatory responses to injuries via the recruitment of immune 
cells (macrophages and fibroblasts)19. We also know that intact Activin A signaling plays an 
important role in controlling cell proliferation in normal, healthy epithelial cells by inhibiting 
proliferation. However, it is increasingly believed that Activin A signaling plays a major role in 
cancer formation and progression.  
Activin A has been shown to participate in inflammation via the activation of NFκB, a 
transcription factor that mediates inflammation. In advanced colorectal cancer, Activin A has 
also been shown to lead to the degradation of p21, an important tumor suppression protein, using 
NFκB and the protein MDM220. 
In lung squamous cell carcinoma, Activin A has been shown to promote metastatic lung cancer 
by inducing and maintaining EMT, which promotes the formation of cancer-initiating 
mesenchymal cells21. In lung adenocarcinoma, a condition histologically comparable to 
esophageal adenocarcinoma, elevated Activin A is correlated to poor patient prognosis19. 
However, Activin A is known for having a complex role in the body. Indeed, Activin A has been 
shown to behave entirely differently depending on the microenvironment. As much as Activin A 
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is known for its pro-metastatic and cancer-initiating roles, it has also been shown in many cases 
to suppress tumor formation. In human breast cancer cells, for example, Activin A has been 
shown to inhibit cancer cell proliferation and promote cell cycle arrest22. In addition, Activin 
signaling and its growth suppressive effects are lost in colon cancer, but is intact and pro-
metastatic in advanced colon cancer as explained above13. 
Such examples show the characteristically complex, context-dependent action of Activin A 
signaling. Whether it plays a prometastatic role or inhibits cancer formation, Activin A is clearly 
involved in tumorigenesis. However, the role of Activin A signaling in the progression of 
esophageal adenocarcinoma, particularly at the early stages induced by gastric reflux-related 
injuries has not been characterized yet. 
The goal of this research project is to characterize the role of Activin A signaling in the context 
of the onset of GERD-related diseases. We also described the link between Activin A and the 
inflammatory response to bile and acid injury in esophageal cells, as well as how this all plays 
out in the progression to Barrett’s esophagus, an important risk factor for esophageal 
adenocarcinoma. Due to the recent discoveries that bile salts and acid injuries increase 
inflammatory cytokine signaling, we hypothesized that GERD-like injuries would cause an 
increase in Activin A signaling, which promotes the inflammatory response and metaplasia to 
BE. 
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MATERIALS AND METHODS 
Cell Culture 
Human esophageal epithelial cells, STR, were cultured in Keratinocyte Serum-Free Medium 
(KSFM) supplemented with 1 ng/ml Epidermal Growth Factor, 0.05 mg/ml Bovine Pituitary 
Extract, and 1% penicillin streptomycin antibiotics (Gibco™, for Life Technologies, Inc., 
Carlsbad, CA). BAR-T cells, a human Barrett’s esophagus cells line (kind gift from Dr. Rhonda 
Souza, Baylor Scott White) were cultured in Epithelial Cell Medium-2 supplemented with 5% 
epithelial cell growth supplement-2 (EpiCGS-2) and 5% penicillin/streptomycin antibiotics 
(ScienceCell™ Research Laboratories, Carlsbad, CA).  All cells were incubated at 37°C with 5% 
CO2. Treatment mimicking gastroesophageal reflux consisted of repeated exposure to acidified 
medium (pH 4 – using 6N hydrochloric acid) and a 100 µM of cocktail of bile salts. The cocktail 
included 20 µM of each, deoxycholic acid (MP Biomedicals, Santa Ana, CA), glycocholic acid, 
taurocholic acid, sodium glycodeoxycholate and sodium glycochenodeoxycholate (All Sigma, St. 
Louis, MO). To establish treatment-tolerant STRs, each treatment was performed for 4 minutes 
in a 37°C incubator with 5% CO2, and then cells are allowed to recover for up to three days and 
the surviving cells are propagated before the next treatment (Trt). The timeline in figure 3 shows 
the treatment progression with time. 
Figure 3: Timeline of bile salts and acid treatment. 
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A8301, a selective TGFβ and Activin A signaling inhibitor (Tocris, Bristol, UK) was added to 
the culture medium at a concentration of 1 µM. Recombinant Activin A (R&D Systems, 
Minneapolis, MN) was used at 10 ng/ml. Both Activin A and A8301 treatments were performed 
continuously for up to 10 days.  
This study used the human esophageal cell line STR as a model for normal esophageal 
epithelium in vitro. The human Barrett’s esophagus cell line BAR-T was used to model the 
Barrett’s esophagus disease state in vitro.  
Protein Analysis 
Cellular Secretion using ELISA 
Changes in the secretion of Activin A and TGFβ by normal esophageal STR cells as a result of 
the bile/acid treatment was studied using the Activin A-specific and TGFβ-specific DuoSet® 
ELISA assays by R&D Systems (Minneapolis, MN).  
ELISA assays detect the amount of protein (Activin A or TGFβ) that cells secrete into their 
environment (the surrounding medium in which they are grown) using specific antibodies. The 
antibodies are also linked to the enzyme horseradish-peroxidase (HRP), which is used for 
visualization. The specific amount of secreted ligand was calculated in pg/ml based on a standard 
curve provided in the kit. 
Cells were exposed to bile and acids for 4 minutes, as described above. They were then allowed 
to recuperate for 30 minutes (Activin A) or 24 hours (TGFβ) in normal KSFM. After this, the 
medium was collected and frozen at -80°C until further analysis.  
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Cell Secretion using Cytokine Array 
Changes in cellular secretion of cytokines of interest were measured using the RayBio® C-Series 
Human Cytokine Antibody Array C6 (RayBiotech, Norcross, GA) and according to the 
manufacturer’s protocol.  
Protein Expression using Western Blotting 
Changes in the expression and/or activation of the proteins involved in various pathways caused 
by the treatments were analyzed via SDS PAGE followed by Western Blotting. To do so, cells 
were lysed 30 minutes after the bile and acid treatment using IP Lysis buffer (150 mM NaCl, 50 
mM Tris, pH 8.0, 1% Triton x-100, 1% NP-40) supplemented with a cOmplete™ EDTA-free 
protease Inhibitor Cocktail tablet. Protein concentration was determined using the Pierce™ BCA 
Protein Assay Kit (ThermoFisher Scientific, Waltham, MA). Subsequently, protein samples were 
separated on a 30% acrylamide gel via SDS PAGE. Gels were transferred to a PVDF membrane 
for western blotting. Proteins were visualized using primary antibodies and HRP-conjugated 
secondary antibodies. 
Protein Role 
Cleaved PARP – Total PARP Apoptosis marker 
Cleaved Caspase 9 – Total Caspase 
9 
Apoptosis marker 
pSmad 2,3 – total Smad 2,3 Direct downstream target of canonical Activin A signaling 
pERK 1/2 – total ERK 1/2 
Involved in cell survival mechanism and non-canonical   
Activin A Signaling 
pStat1 – Stat1 (C-terminus) Inflammation-inducing transcription factors 
pStat3 – Total Stat3 Inflammation-inducing transcription factors 
NFκB p65 Transcription factor involved in Inflammation 
COX2 Elevated during inflammation 
Sox9 Marker for columnar epithelial differentiation 
 
Table 1: Markers used for Western Blot analysis19, 23, 24. 
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Markers involved in the Activin A pathway, markers of stemness and reprogramming, 
inflammation markers, and apoptosis markers were analyzed (table 1). 
Gene Expression Analysis 
The exposure of acidic bile salts to esophageal cells has been shown to induce significant DNA 
damage25. We investigated the impact of acid and bile salts exposure on gene expression using 
RNA isolation and two-step qRT-PCR.  For this, total RNA was extracted and purified from 
STR and BAR-T cells 30 minutes post-treatment via phenol and guanidine thiocyanate extraction 
using the miRNeasy® Mini Kit (Qiagen, Santa Clara, CA) according to the manufacturer’s 
protocol. 
Name 
Forward - F 
Reverse - R 
Sequence (5'-3') 
TNFα F GAA TTC GGA CAC CAT GAG CAC TG 
  R GGA TCC ACC GGT TCA CAG GGC AAT GAT CCC 
ILβ F ATG ATG GCT TAT TAC AGT GGC AA 
  R GTC GGA GAT TCG TAG CTG GA 
Cox2 F TGA GCA TCT ACG GTT TGC TG 
  R TGC TTG TCT GGA ACA ACT GC 
Sox9 F CAT GAG CGA GGT GCA CTC C 
  R TCG CTT CAG GTC AGC CTT G 
LGR5 F AAC AGT CCT GTG ACT CAA CTC AAG 
  R TTA GAG ACA TGG GAC AAA TGC CAC 
DCLK1 F AGT CTT CCG ATT CCG AGT TGA G 
  R CAG CAA CCA GGA ATG TAT TGG A 
 
Table 2: Primers used in qRT-PCR 
Reverse transcription was performed to obtain a cDNA library of the samples using the 
QuantiTect® Reverse Transcription Kit (Qiagen, Santa Clara, CA). Real time qRT-PCR was 
then performed using the QuantiTect SYBR® Green PCR kit by Qiagen. The genes Rpl13A and 
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Eif3d were amplified as internal controls. We investigated several genes from the Activin A 
pathway, inflammatory markers, and stem cell markers using this method (table 2) 
Functional Assays 
Functional assays were useful to determine the effect of changes in Activin A signaling on the 
characteristics and properties of the cells. The functional assays used for this study were 
proliferation assays as well as Boyden chamber assays. 
Proliferation Assays 
Proliferation assays were performed in order to determine the effect of the bile salts and acid 
treatments, as well as the hypothesized increase in Activin A signaling, on the proliferative 
capacity of the esophageal cells. This experiment was performed using a Click-iT® EdU kit 
(Invitrogen, Carlsbad, CA) and according to the manufacturer’s protocol.  
In this assay, a DNA intercalating agent (Click-iT® Alexa Fluor® azide) gets selectively 
incorporated in the nucleus of actively dividing cells, which are in the S phase of the cell cycle, 
therefore staining for actively proliferating cells.  The assay was performed on cells after 
repeated exposure to bile salts and acid and compared to an untreated control. The effect of 
Activin A signaling on cell proliferation was studied using A8301, a selective Activin A 
signaling inhibitor, and recombinant Activin A. 
Particularly, the cells were exposed to EdU for 7 hours, and fixed immediately after. Cells were 
stained with EdU for 30 minutes. Overall DNA was stained with Hoechst overnight at 4°C. For 
analysis, the ratio of EdU positive cells to total cells (visualized using overall DNA staining) was 
calculated. All calculations were made in triplicates and using biological replicates. 
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Additionally, the viability of the cells over time as a result of the repeated treatments was studied 
using western blotting. For apoptosis markers, cell lysates were collected 4 hours post-treatment 
(table 1). 
Boyden Chamber Assays 
The ability of cells to migrate through a reconstituted extracellular matrix (ECM) was measured 
using BioCoat™ Matrigel® Invasion Chambers (Corning, Corning, NY) and according to the 
manufacturer’s protocol.   
These Boyden chambers use a chemoattractant to cause migration of cells through a porous 
membrane and a reconstituted ECM. Particularly, 105 cells were plated on the top insert and 
allowed to migrate through the Matrigel basement membrane. All conditions were performed in 
triplicate inserts.  
For analysis, the number of cells that had migrated through the ECM was counted in four 
microscopic fields per insert (10X magnification), with three replicate inserts per condition. The 
role of Activin A signaling was evaluated using A8301 and recombinant Activin A. The results 
were used to describe the ability of cells to migrate through upon a extracellular protein matrix 
such as an epithelial basement membrane26.  
Statistical Analysis 
Biostatistical analysis was performed using Prism version 6.00 for Mac. Experiments were 
analyzed using Student’s t-tests or one-way ANOVAs. Statistical significance was set at p<0.05. 
All experiments were done in triplicates or duplicates with at least three biological replicates.  
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RESULTS 
Characterization of Long-Term Treated Esophageal Epithelial Cells 
STR esophageal epithelial keratinocytes were treated with acidified medium (pH 4 – reflecting 
the acidity of stomach refluxate into the esophagus) and a cocktail of bile salts (see materials and 
methods) as an in vitro model for acid reflux. In this model system, each exposure of cells to 
acid and bile salts reflects a reflux episode in a GERD patient.  
 
In order to mimic chronic exposure of the cells and determine any long-term changes, a protocol 
for repeated and consecutive treatments was developed. To begin with, cells were not tolerating 
the treatment very well: treated cells died significantly faster than control cells, particularly after 
Figure 4: Long term-treated 
esophageal epithelial cells 
become tolerant after initial 
apoptosis induced by 
bile/acid. A-B: Apoptosis 
markers Cleaved PARP and 
Cleaved Caspase 9 were 
drastically reduced after the 
third treatment. 
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a treatment. After each round of treatment, the surviving cells were kept and propagated for the 
next treatment.  
Interestingly, we observed in culture that after each consecutive treatment, cell death seemed to 
gradually reduce.  
In order to quantify this adaptation and apparent tolerance, cell lysates were collected after six 
consecutive treatments and apoptosis markers were probed via western blotting (figure 4). It was 
therefore determined that after a point of crisis, where significant cell death occurred, the 
propagated cells were able to better tolerate the treatment. Such tolerant cells were used for all 
further experiments. 
Activin A Signaling is Induced upon Bile and Acid Injury and Promotes Wound 
Healing 
The first bit of evidence linking Activin A to acute inflammation came when Jones et al. 
discovered that serum levels of Activin A increased significantly within 1 hour of an injection of 
bacterial lipopolysaccharide (LPS) in sheep27. Since then, a variety of data and evidence suggests 
that this cytokine plays an integral role in several inflammatory processes. However, the role of 
Activin A signaling in GERD-related diseases has never been described, and formed the central 
goal of this research project.  
As mentioned, the Activin A pathway proceeds via two distinct routes. The first one goes 
through the cytoplasmic Smad proteins, and is the canonical pathway of Activin A signaling. 
Particularly, Smad2/3 gets phosphorylated during signaling, and the phosphorylated complex 
gets translocated to the nucleus to act as a transcription factor and mediate signal response. 
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Interestingly, our data shows that bile salts and acid treatment of esophageal keratinocytes 
triggers the canonical pathway of Activin A signaling within 30 minutes (figure 5-A).  
Additionally, Activin A also proceeds via a non-canonical pathway for signaling, which involves 
the mitogen-activated protein kinase (MAPK) pathways. Similarly, we also observed an increase 
in phosphorylation of ERK protein, which is a direct target of the MAPK pathway, 30 minutes 
after exposure to bile salts and acid (figure 5-B).  
In subsequent experiments using an Activin A inhibitor, we found that inhibiting Activin A 
signaling does not inhibit ERK phosphorylation (see supplemental data). This would indicate 
Figure 5: Acid and bile salts treatment activates Activin A signaling. A: Direct, 
canonical downstream target Smad 2/3 gets phosphorylated, indicating Activin A 
signaling. B: Non-canonical downstream target of Activin A, ERK, is also activated 
upon treatment. C: Treated STR cells repeatedly secreted more Activin A.  
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that the activation of the non-canonical pathway of Activin A during acid reflux was not caused 
by Activin A signaling alone. 
To confirm that the bile and acid treatment triggered Activin A signaling, an ELISA assay was 
performed using conditioned medium of cultured cells. Once more, the data showed an increase 
in secreted Activin A 30 minutes post-treatment (figure 5-C). Together, our data suggests that 
bile and acid treatment causes an increase in Activin A secretion by the esophageal keratinocytes 
that disrupts the normal signaling of the Activin A pathway.  
We subsequently hypothesized that the dysregulated signaling pathway could have an impact on 
wound healing as a response of the epithelium to the bile and acid injury. We therefore tested if 
the bile salts and acid treatment had caused any changes in the ability of cells to migrate through 
an extracellular protein matrix such as the basement membrane of a stratified epithelium. To do 
Figure 6: Migration of bile and acid treated cells on a reconstituted protein matrix. 
A: Treated STR cells migrated faster through the reconstituted ECM. B: Upon 
treatment with Activin A inhibitor A8301, cells migrated significantly slower. On 
the other hand, normal cells treated with recombinant Activin A migrated faster.  
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so, treated cells were placed in a Boyden chamber and their ability to migrate through a 
reconstituted extra-cellular matrix was measured.  
In figure 6-A, the data showed that the bile and acid treatment caused changes in the cells 
rendering them able to better migrate through a surrounding matrix.  
A subsequent experiment was performed to determine if the increased migration through the 
basement membrane is Activin A-dependent (figure 6-B). Here, the data shows that inhibiting 
Activin A signaling using A8301 was capable of knocking the migration back down to normal 
levels. On the contrary, treating cells with recombinant Activin A increased the migration across 
the basement membrane significantly.  
As mentioned above, the inhibitor A8301 shows broad-specificity for members of the TGFβ 
superfamily. In other words, A8301 targets and inhibits receptors for Activin A signaling 
(including Activin Receptors IB and IC), but also another receptor for the TGFβ ligand (TGFβ 
Receptor IB). Signaling by the TGFβ ligand is therefore also inhibited by A8301.  
In order to ensure specificity of the inhibitor for Activin A alone, we analyzed the amount of 
TGFβ ligand secreted by STR cells. As such, we performed TGFβ-specific ELISA assays on 
conditioned medium of both treated and untreated STR cells. Data from this experiment showed 
very low, non-detectable levels of secreted TGFβ by STR cells across all conditions. Little to no 
TGFβ was secreted by untreated STR cells, at 30 minutes as well as 24 hours post treatment. 
This result suggested that the A8301 inhibitor used in these experiments specifically disrupted 
Activin A signaling of STR cells. 
20 
 
Chronic Inflammation Caused by Bile and Acid Injury and Activin A 
In the early theories about the progression of GERD to Barrett’s esophagus and finally to 
esophageal adenocarcinoma, much importance was accorded to the role of physical damage and 
erosion that occurred during acid reflux. It was thought that this damage caused degradation of 
normal surface epithelial cells, which would then promote the invasion of immune cells and 
therefore cause inflammation10. 
More recently, it has been shown that instead of causing erosion and mechanical injury, the 
gastric reflux from GERD causes epithelial cells to release inflammatory cytokines, which would 
themselves induce the inflammatory response, and be responsible for disease progression10.  
In addition, previous literature has shown that increased Activin A signaling mediates increased 
inflammation and fibrosis in injured tissue28, but this was never shown in esophageal epithelium. 
We therefore hypothesized that the observed increase in Activin A signaling in the treated cells 
could also trigger a disruption of inflammatory markers.  
We used three different approaches to assess the impact of bile salts and acid on inflammatory 
pathways. Namely, western blotting (figure 7 – A-D), inflammatory cytokine array (figure 7-E) 
and qRT-PCR (figure 7-F). Interestingly, we found that bile salts and acid treated cells had 
several upregulated inflammatory markers.  
Particularly, the bile salts and acid treatment triggered more phosphorylation of the Stat1 and 
Stat3 proteins, and caused an increase in expression of both NFκB and COX-2 (figure 7 – A-D).  
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In addition, the cytokine array showed that the treatment caused a significant upregulation of 
GM-CSF, INF-γ, the Interleukins 1α, 1β, 2, 3, 6, 7, and 16, as well as TNFα and TNFβ (figure 7-
E).  
Finally, the treatment also caused an upregulation of gene expression for several inflammatory 
cytokines, at the mRNA level (figure 7-F), namely for TNFα, IL-1β, as well as COX-2. 
Interestingly, when the treated cells were also treated with the Activin A inhibitor A8301, the 
upregulation of IL-1β and Cox-2 seemed to also be inhibited. However, treating normal cells 
alone with recombinant Activin A did not cause any change in the expression of these 
inflammatory cytokines. This data suggests that the increase in Activin A signaling caused by the 
treatment may be partly responsible for the increased inflammation of the treated cells.  
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In contrast, the inhibition of Activin A signaling actually caused an even greater increase in the 
gene expression of TNFα. Conversely, adding recombinant Activin A to the normal STR cells 
Figure 7: Bile salts and 
acid treatment causes 
increased inflammation 
in STR cells. A-D: 
Treatment with bile 
salts and acid caused an 
elevation of several 
inflammatory markers. 
E: Cytokine array on 
conditioned medium of 
treated cells showed 
upregulation of a variety 
of inflammatory 
markers. 
F: Several genes 
involved in 
inflammation were also 
upregulated after the 
bile and acid treatment. 
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actually caused a decrease in TNFα expression. 
Put together, our data suggests that even though it seems that Activin A may play a role in the 
increased inflammation of STR cells (IL-1β, Cox-2), it is also likely that it is not the only 
contributor. Additionally, the role of Activin A signaling in part may be indirect, as previously 
reported (Activin A signaling can be context dependent). 
Activation of Stem Cells as Result of Bile and Acid Injury 
The proliferative capacity is one of the hallmarks of cancer, and important for the repair of an 
injured epithelium.  We performed experiments in order to measure cell growth and determine if 
it is affected by the bile and acid treatment or the increased Activin A signaling. 
In culture, we observed that the treatment tended to have a negative effect on cell proliferation. 
After each treatment, cells were “shocked”, and it took a little time for them to recover. We 
found that during this time, cells divided slower and therefore proliferated less.  
We performed experiments to quantify this seemingly lower post-treatment proliferation. The 
experiment involved a DNA intercalating agent EdU that is incorporated only in actively 
dividing, proliferating cells. Using this method, we showed that the cells did in fact have a 
reduced proliferation rate during the recovery time from an exposure to bile salts and acid 
(figure 8-A and C). In addition, we analyzed whether or not the increase in Activin A signaling 
affected cell proliferation in any way (figure 8-B). Treating the bile and acid-tolerant cells with 
the Activin A inhibitor A8301 did not bring the proliferation rate back up to normal levels. 
However, when we treated normal cells with recombinant Activin A, cell proliferation decreased 
significantly, and it was comparable to the drop of the bile and acid treated cells. This data 
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suggests that Activin A may also play a role in this decreased proliferation, but that the treatment 
with bile and acid also damaged the cells enough to decrease their proliferation rate. 
Stem cells and progenitor cells are known for being slow cycling and proliferating slowly29. Our 
finding about the reduced proliferation and therefore slower cell cycle in treated cells led us the 
Figure 8: Bile salts and 
acid treatment caused 
reduction of proliferation 
in STR cells. A: Treating 
the cells with bile salts 
and acid resulted in a 
decrease in proliferation, 
as indicated by a 
decrease in actively 
dividing cells. B: The 
decrease in proliferation 
caused by the bile salts 
and acid treatment may 
be Activin A- related. 
Inhibiting Act. A 
signaling did not bring 
the proliferation back up, 
but treating normal cells 
with recombinant Act. A 
also dropped the number 
of proliferating cells. C: 
Qualitative 
representation of data in 
frame A. Actively 
proliferating cells are 
stained in green.  
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hypothesize that the bile and acid treatment, as well as increased Activin A signaling, could lead 
to an resurgence of stem cell features, and increased plasticity, possibly involving de-
differentiation back into an epithelial stem cell-like state. This hypothesis is consistent with the 
latest research on the potential source of Barrett’s esophagus stem cells as well as theories on 
plasticity among differentiated adult epithelial cells. We investigated this hypothesis using 
western blotting and qRT-PCR, looking at the levels of stem cell markers in the treated cells 
Figure 9: Treatment with bile salts and acid induces upregulation of stem cell markers. 
A-C: Treated cells displayed an increase in stem cell markers. Inhibition of Act. A 
signaling using A8301 in treated cells tends to bring back the stem cell markers to 
normal levels, indicating a potential Activin A involvement. 
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(figure 9). Interestingly, we observed an increase in Sox9 in the bile and acid treated cells 
(figure 9-A). Sox9 is known for being overexpressed in Barrett’s esophagus tissues. In 
esophageal squamous tissues, it is a known marker for columnar metaplasia24.  
We also found that treating the cells with bile salts and acid significantly increased the stem cell 
markers DCLK and LGR5. LGR5 is known to be overexpressed in gastrointestinal stem cells 
and for being a marker for intestinal metaplasia30. DCLK has also been shown to be a 
gastrointestinal stem cell marker31.  
Finally, another interesting point was that inhibiting Activin A signaling using A8301 usually 
caused a diminishing of these upregulations. However, Activin A alone usually was not enough 
to cause a significant increase in stem markers (figure 9 – A-B), but did trigger an increase in 
LGR5 that was similar to the bile and acid treatment (figure 9-C). 
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DISCUSSION & CONCLUSIONS 
The data presented in this paper shed light on the involvement of Activin A signaling in GERD-
associated diseases. Our results suggest that repeated bile salts and acid exposure on esophageal 
squamous keratinocytes triggers an increase in secretion of the Activin A cytokine. This causes 
changes in several cell characteristics including cell invasion and the activation of stem cell 
markers as part of the injury repair.  
Dysregulated cytokine signaling has been previously shown to be responsible for inflammation 
in a GERD-like setting10, and Activin A itself has been shown to promote inflammation and 
fibrosis in other diseases and in skin wound healing19, 20, 28. This study was the first performed on 
the Activin A cytokine in the context of gastroesophageal reflux disease.  
Our data provides support for the latest theory about the onset of GERD-related disease, namely 
that esophageal epithelial cells can be responsible for promoting inflammation through cytokine 
secretion upon being injured by bile salts and acid from the gastric reflux. In addition, the data 
shown here provides the first evidence that the Activin A cytokine is involved in promoting 
inflammation in a GERD-related context. Indeed, we found Activin A to be increasingly secreted 
upon bile salts and acid injuries. We also found that several inflammatory markers were 
upregulated. Upon inhibiting Activin A signaling in the bile and acid treated cells, we observed 
that several inflammatory markers were in turn significantly reduced back to near normal levels.  
The origin of Barrett’s esophagus and the source of the progenitor stem cells that eventually lead 
to BE remains unknown and is the subject of intense research. Briefly, there are have been 
several proposed theories. The first one proposes that the acid and bile salts from the gastric 
28 
 
reflux injures the esophageal epithelium, and causes mature, differentiated squamous cells to 
undergo molecular reprogramming into a columnar type of epithelium, a process called 
transdifferentiation. This theory proposes the same idea for immature esophageal epithelial cells, 
found in the basal layer epithelium tissues. In this case, the gastric reflux injury causes these 
undifferentiated cells to develop into columnar cells rather than squamous cells. This process is 
called transcommitment24.  
The other theories include that Barrett’s esophagus progenitor cells actually come from the 
gastric cardia. Stem cells from the gastric cardia, which are programmed columnar epithelial 
cells, are proposed to have migrated up into the esophagus and caused BE. Another theory 
proposes that residual embryonic stem cells expand into the esophagus and form the source of 
the BE tissue. Another theory is that intermediate-type cells from the squamo-columnar junction 
form the source of the BE cells. Finally, it is suspected that circulating bone marrow stem cells 
may settle into the injured tissue and differentiate into columnar, Barrett’s tissue24.  
Our data gives support to the theory that BE stem cells originate from the existing squamous 
epithelial tissue. The cells used in our model are differentiated squamous esophageal epithelial 
cells. However, upon treating them with a GERD-like mixture of bile salts and acid, gene 
expression for the gastrointestinal stem cell markers DCLK and LGR5 was elevated. In addition, 
the epithelial columnar metaplasia marker Sox9 was also upregulated. These results provide 
evidence for the transdifferentiation theory of BE stem cell source.  
The concept of transdifferentiation is tightly linked to a brand-new theory in the field termed 
paligenosis. In short, the paligenosis theory states that much like the apoptosis pathway, 
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differentiated cells contain a molecular pathway, which, when triggered by injury, enables cells 
to achieve dedifferentiation into a progenitor cell-like state, rendering them able to change into a 
different cell type5, 32-34.  
The pathway first involves a metaplastic-inducing injury such as gastric reflux. Then, this causes 
a decrease in the mTORC1 pathway activity and a substantial upregulation of lysosomes. Then, 
damage-associated genes and stem cell genes, such as for example Sox9, are activated. Finally, 
the mTORC1 pathway is reactivated and the cell re-enters the cell cycle5. This pathway has been 
shown to be conserved across many tissues and cell types. Paligenosis has therefore been 
proposed as a mechanism as conserved as the apoptosis mechanism, across all cells32.  
This theory gives an explanation to the plasticity observed in cells from many different tissues, 
including the esophagus. In the context of esophageal diseases, paligenosis would enable what 
we originally believed as terminally differentiated cells, such as those in the esophageal 
squamous epithelium, to undergo a metaplastic change and give rise to a metaplastic tissue of a 
different cell type such as the one seen in BE.   
The data presented in this paper do support the notion of paligenosis. Our findings of the 
upregulation of stem cell markers and the decrease in proliferation of differentiated esophageal 
epithelial cells caused by exposure to bile salts and acid, both support this new theory. A future 
direction for this study would be to dive deeper into the link between gastric reflux-related 
diseases, transdifferentiation, transcommitment and paligenosis. This could provide more 
information into the origin of metaplastic Barrett’s esophagus cells, which are important 
contributors to the formation of esophageal adenocarcinoma.   
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APPENDIX: SUPPLEMENTAL DATA 
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Figure 10: A8301 can inhibit the upregulation of canonical Activin A signaling, but not of non-canonical 
signaling. A: Canonical Activin A signaling is upregulated by bile salts and acid exposure. A8301 inhibitor 
can bring this upregulation back down. B: Non-canonical Activin A signaling is upregulated by bile salts 
and acid exposure. A8301 inhibitor was unable to bring it back down.  
32 
 
REFERENCES 
1. Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, 
staging workup and treatment modalities. World J Gastrointest Oncol 2014;6:112-20. 
2. National Cancer Institue. Cancer Stat Facts: Esophageal Cancer, 2014. 
3. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal 
reflux disease: a systematic review. Gut 2014;63:871-80. 
4. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013;19:5598-606. 
5. Willet SG, Lewis MA, Miao ZF, et al. Regenerative proliferation of differentiated cells by 
mTORC1-dependent paligenosis. Embo j 2018;37. 
6. Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal 
Adenocarcinoma. Gastroenterology 2015;149:302-317.e1. 
7. Lagergren  J, Bergström  R, Lindgren  A, et al. Symptomatic Gastroesophageal Reflux as a Risk 
Factor for Esophageal Adenocarcinoma. New England Journal of Medicine 1999;340:825-831. 
8. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with 
symptoms of gastro-oesophageal reflux. Alimentary Pharmacology & Therapeutics 
2010;32:1222-1227. 
9. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) 
esophagus. N Engl J Med 1985;313:857-9. 
10. Souza RF, Huo X, Mittal V, et al. Gastroesophageal Reflux Might Cause Esophagitis Through a 
Cytokine-Mediated Mechanism Rather Than Caustic Acid Injury. Gastroenterology 
2009;137:1776-1784. 
11. Huo X, Zhang X, Yu C, et al. In oesophageal squamous cells exposed to acidic bile salt medium, 
omeprazole inhibits IL-8 expression through effects on nuclear factor-kappaB and activator 
protein-1. Gut 2014;63:1042-52. 
12. Souza RF, Bayeh L, Spechler SJ, et al. A new paradigm for GERD pathogenesis. Not acid injury, 
but cytokine-mediated inflammation driven by HIF-2α: a potential role for targeting HIF-2α to 
prevent and treat reflux esophagitis. Curr Opin Pharmacol 2017;37:93-99. 
13. Dunbar KB, Agoston AT, Odze RD, et al. Association of Acute Gastroesophageal Reflux Disease 
With Esophageal Histologic Changes. Jama 2016;315:2104-12. 
14. Souza RF, Shewmake K, Terada LS, et al. Acid exposure activates the mitogen-activated protein 
kinase pathways in Barrett's esophagus. Gastroenterology 2002;122:299-307. 
15. Morgan C, Alazawi W, Sirieix P, et al. In vitro acid exposure has a differential effect on apoptotic 
and proliferative pathways in a Barrett's adenocarcinoma cell line. Am J Gastroenterol 
2004;99:218-24. 
16. Jaiswal K, Lopez-Guzman C, Souza RF, et al. Bile salt exposure increases proliferation through 
p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest 
Liver Physiol 2006;290:G335-42. 
17. Kazumori H, Ishihara S, Rumi MA, et al. Bile acids directly augment caudal related homeobox 
gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 2006;55:16-25. 
18. Jolly AJ, Wild CP, Hardie LJ. Acid and bile salts induce DNA damage in human oesophageal cell 
lines. Mutagenesis 2004;19:319-24. 
19. Loomans HA, Andl CD. Intertwining of Activin A and TGFbeta Signaling: Dual Roles in Cancer 
Progression and Cancer Cell Invasion. Cancers (Basel) 2014;7:70-91. 
33 
 
20. Jana A, Krett NL, Guzman G, et al. NFkB is essential for activin-induced colorectal cancer 
migration via upregulation of PI3K-MDM2 pathway. Oncotarget 2017;8:37377-37393. 
21. Wamsley JJ, Kumar M, Allison DF, et al. Activin upregulation by NF-kappaB is required to 
maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer. Cancer 
Res 2015;75:426-35. 
22. Chen L, Zhang W, Liang HF, et al. Activin A induces growth arrest through a SMAD- dependent 
pathway in hepatic progenitor cells. Cell Commun Signal 2014;12:18. 
23. Seif F, Khoshmirsafa M, Aazami H, et al. The role of JAK-STAT signaling pathway and its 
regulators in the fate of T helper cells. Cell Commun Signal 2017;15:23. 
24. Wang DH, Souza RF. Transcommitment: Paving the Way to Barrett's Metaplasia. Adv Exp Med 
Biol 2016;908:183-212. 
25. Bhardwaj V, Horvat A, Korolkova O, et al. Prevention of DNA damage in Barrett's esophageal 
cells exposed to acidic bile salts. Carcinogenesis 2016;37:1161-1169. 
26. Justus CR, Leffler N, Ruiz-Echevarria M, et al. In vitro cell migration and invasion assays. J Vis Exp 
2014. 
27. Jones KL, Brauman JN, Groome NP, et al. Activin A release into the circulation is an early event in 
systemic inflammation and precedes the release of follistatin. Endocrinology 2000;141:1905-8. 
28. de Kretser DM, O'Hehir RE, Hardy CL, et al. The roles of activin A and its binding protein, 
follistatin, in inflammation and tissue repair. Mol Cell Endocrinol 2012;359:101-6. 
29. Vitale I, Manic G, De Maria R, et al. DNA Damage in Stem Cells. Mol Cell 2017;66:306-319. 
30. Jang BG, Lee BL, Kim WH. Distribution of LGR5+ cells and associated implications during the 
early stage of gastric tumorigenesis. PLoS One 2013;8:e82390. 
31. Westphalen CB, Quante M, Wang TC. Functional implication of Dclk1 and Dclk1-expressing cells 
in cancer. Small GTPases 2017;8:164-171. 
32. Burclaff J, Mills JC. Plasticity of differentiated cells in wound repair and tumorigenesis, part I: 
stomach and pancreas. Dis Model Mech 2018;11. 
33. Burclaff J, Mills JC. Plasticity of differentiated cells in wound repair and tumorigenesis, part II: 
skin and intestine. Dis Model Mech 2018;11. 
34. Messal HA, Cremona CA, Lan L, et al. Paligenosis: prepare to regenerate! Embo j 2018;37. 
 
